A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease

UCB

Status and phase: Completed; Phase 3

Conditions: Parkinson's Disease

Treatments: Drug: PARCOPA

Study type: Interventional

Funder types: Industry

Identifiers

NCT00139867

SP0780

Details and patient eligibility

About

The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets, in subjects with stable Parkinson's disease.

Full description

See approved Package Insert for Adverse Event information.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Stable Parkinson's Disease

Exclusion criteria

• Not using carbidopa/levodopa tablets